The global Bulimia Nervosa Treatment Market exhibited considerable strength in 2021 and is anticipated to maintain a swift growth trajectory in terms of revenue Compound Annual Growth Rate (CAGR) throughout the forecast period. This growth is primarily fueled by the escalating prevalence of eating disorders among the elderly population, heightened research and development efforts aimed at pioneering innovative therapeutic approaches, and the pressing need for authentic and approved medications to address bulimia nervosa, which continues to hinder market revenue expansion.
Bulimia nervosa, a severe eating disorder colloquially referred to as bulimia, poses a grave health risk. Those afflicted with bulimia often engage in secretive cycles of binge-eating followed by purging in an attempt to eliminate the consumed calories through unhealthy means. Binge-eating involves the consumption of excessive quantities of food without self-control. Manifesting an intense preoccupation with body weight and shape, accompanied by an intense fear of gaining weight, individuals resort to self-induced vomiting, excessive exercise, or other extreme measures after binging. Additional symptoms include the repeated consumption of abnormally large meals, utilization of laxatives, diuretics, or enemas after eating episodes, and a profound impact on mental and physical well-being.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5505
The Growth Catalysts: Driving Factors- Several factors contribute to the burgeoning revenue in the bulimia nervosa treatment market. A significant driver is the escalating prevalence of the disorder itself. Data reveals a lifetime prevalence of 1.0% for bulimia nervosa among adults, with an overall prevalence of 0.3%. Notably, females exhibit a fivefold higher prevalence (0.5%) compared to males (0.1%). The available medications in the market cater to addressing impairments in the quality of life experienced by patients. According to the Sheehan Disability Scale, approximately 43.9% of individuals with bulimia nervosa experience severe impairment, while 78.0% face some form of disability. Moreover, symptomatic treatment through antidepressants plays a crucial role in preventing complications associated with bulimia nervosa. The years spanning from 2015 to 2018 witnessed a 13.2% usage of antidepressants among adults, with higher usage among women (17.7%) than men (8.4%). Antidepressant use also exhibited an upward trend with increasing age brackets, with percentages rising from 7.9% among those aged 18 to 39, to 14.4% in the 40 to 59 age group, and finally to 19.0% among those aged 60 and above. These factors collectively contribute to the growth of the bulimia nervosa treatment market.
Limiting Factors- Conversely, there exist various factors restraining the revenue growth in the bulimia nervosa treatment market. A pivotal concern is the paucity of specific treatments available in emerging economies. Furthermore, the presence of diverse therapies, such as psychotherapy, poses a hindrance to revenue expansion. Limited awareness of the disorder among medical practitioners and patients alike impedes swift and accurate diagnosis. Additionally, the costly nature of bulimia nervosa treatment regimens negatively impacts market growth. The side effects associated with antidepressant medications used for symptomatic relief also pose a setback to revenue expansion.
Emerging Opportunities: The surge in research and development endeavors within the pharmaceutical sector, aimed at advancing bulimia nervosa treatment methods, offers significant growth opportunities for the market. Increased governmental involvement in healthcare enhancement on a global scale also contributes to the industry's growth trajectory. The unique symptom profile of each patient opens the door for personalized treatment approaches, presenting an avenue for scientists and innovators to develop more effective medications for individuals with bulimia nervosa, thereby sustaining revenue growth.
Regional Market Landscape: Dominant Market Share: North America is poised to capture the largest share of revenue in the forecast period, underpinned by the introduction of novel treatment options within the region. This is further bolstered by higher healthcare expenditures and an array of available treatment choices, all of which contribute to driving market revenue growth. Enhanced awareness about the disorder has also played a pivotal role in boosting market revenues in the region.
Fastest Growth Region: The Asia Pacific region is anticipated to exhibit a remarkable revenue CAGR during the forecast period. Countries like China and India are witnessing a notable increase in their geriatric populations. The presence of generic drug manufacturers, coupled with the expansion of healthcare facilities, fuels revenue growth in the region.
Key Trends and Innovations: Ongoing clinical trials, such as the phase 4 trial evaluating the efficacy of serotonergic antidepressants in bulimia nervosa, demonstrate the commitment to advancing treatment methods. A phase 2 clinical trial investigating the effects of estradiol (E2) and progesterone (P4) on binge eating in women with bulimia suggests the hormone-sensitive nature of the disorder, guiding future research in neuroendocrinology and brain function pertaining to bulimia nervosa.
Competitive Landscape: Companies in the market have adopted both organic and inorganic strategies to bolster their positions. Notably, the U.S. Food and Drug Administration (FDA) has approved fluoxetine (Prozac), a selective serotonin reuptake inhibitor, as the sole antidepressant for treating bulimia nervosa. In 2019, two major U.S.-based eating disorder support groups, the National Eating Disorders Association (NEDA) and the National Association for Males with Eating Disorders (NAMED), merged to enhance community support.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5505
Key Market Players: The bulimia nervosa treatment market features prominent players like AstraZeneca plc, Sun Pharmaceutical Industries Ltd, GSK plc, Eli Lilly & Company, Bayer AG, Pfizer Inc., Sorrento Therapeutics, Inc., Johnson & Johnson, and Lupin Limited.
Comprehensive Market Insights: Our report presents historical data, forecasts, and revenue growth analysis at global, regional, and country levels. It offers insights into industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenues, and revenue shares by region and country from 2019 to 2030. The report encompasses industry analysis, competitive landscape, company financials, and impact assessments.
Insights by Distribution Channel (Revenue, USD Billion; 2019-2030):
- Online
- Offline
End-Use Insights (Revenue, USD Billion; 2019-2030):
- Hospitals
- Specialty Clinics
- Homecare
- Others
Disease Type Insights (Revenue, USD Billion; 2019-2030):
- Purging
- Non-purging
Route of Administration Insights (Revenue, USD Billion; 2019-2030):
- Oral
- Parenteral
- Others
Treatment Outlook (Revenue, USD Billion; 2019-2030):
- Antidepressants
- Antipsychotics
- Selective serotonin reuptake inhibitor
- Serotonin-norepinephrine reuptake inhibitor
- Benzodiazepines
- Others
Dosage Form Insights (Revenue, USD Billion; 2019-2030):
- Tablets
- Injections
Regional Insights (Revenue, USD Billion; 2019-2030):
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- U.A.E.
- South Africa
- Rest of Middle East & Africa
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5505
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Recombinant Human Serum Albumin Market
Cellulite Reduction Devices Market
Intranasal Drug and Vaccine Delivery Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
